4 / 5 Stars
5 5 5 5 3
Zacks Investment Research
1 (Strong Buy)
Standard & Poor's
4 / 5 Stars
U.S. News evaluated 33 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
The fund has returned 44.58 percent over the past year, 26.64 percent over the past three years, 23.75 percent over the past five years, and 11.31 percent over the past decade.
|Trailing Returns||Updated 06.30.2014|
|Year to date||13.2%|
|3 Years (Annualized)||26.6%|
|5 Years (Annualized)||23.8%|
|10 Years (Annualized)||11.3%|
The investment seeks long-term growth of capital. The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets in securities of companies that the portfolio manager believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.
Fees are Low compared to funds in the same category.
Janus Global Life Sciences Fund has an expense ratio of 1.83 percent.
Risk is Above Average compared to funds in the same category according to Morningstar.